NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.97 -0.03 (-0.04%) GOLD FUTURES
2,313.70 +2.70 (+0.12%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,329.02 +1,772.68 (+3.89%)
AstraZeneca PLC (AZNCF)
- Business Wire
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).
- Business Wire
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as
- Fool.co.uk
£20,000 in cash? Here’s how I’d aim for £10,000 in annual passive income!
Our writer explains how he'd maximise his investment allowance in a Stocks and Shares ISA to target £10k in tax-free passive income every year. The post £20,000 in cash? Here’s how I’d aim for £10,000 in annual passive income! appeared first on The Motley Fool UK.
